

Global Conjunctivitis Drugs Market 2018-2024

<https://marketpublishers.com/r/G0CDBE1278BEN.html>

Date: June 2018

Pages: 82

Price: US\$ 2,750.00 (Single User License)

ID: G0CDBE1278BEN

Abstracts

Global Bacterial Conjunctivitis Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast: 2018–2024

Overview: Bacterial conjunctivitis is a contagious eye infection in which the conjunctiva of one or both the eyes are infected by bacteria such as Staphylococci, Gonococci, Chlamydia, and Streptococci. The infection caused by Chlamydia trachomatis and Neisseria gonorrhoea species are extremely severe. However, there are many antibiotics that help in curing these conditions, thus ensuring quicker clearance of the indications of infection. Healio reported that nearly 5 million bacterial conjunctivitis cases are registered every year. There are many antibiotics currently used for the treatment, which include Besivance, Zymaxid, Maxitrol, and AzaSite. These antibiotics can be administered via oral, transdermal, and otic.

Although, most of the bacterial conjunctivitis are self-limiting, yet topical antibiotics are suggested to cut the duration of the disease and avoid the spreading of infection. A wide range of antibiotics are generally used as a primary treatment option for bacterial conjunctivitis. Topical antibiotics are suggested to deliver the highest dose of the drug straight to the infection site, more than what is usually achieved by oral and other routes. Consequently, the broad spectrum of antibiotic of a single drug is improved.

Market Analysis: The “Global Bacterial Conjunctivitis Drugs Market” is estimated to witness a CAGR of 2.1% during the forecast period 2018–2024. The bacterial conjunctivitis drugs market is analyzed based on two segments – drug class and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America accounts for the largest share of the bacterial conjunctivitis market, followed by Europe, Asia Pacific, and Rest of the

World. More than 40% of the market is occupied by North America, with the US being the major contributor to the market growth.

Drug Class Analysis: Based on drug classes, the market is segmented into fluoroquinolones, aminoglycosides, macrolides, and others. Fluoroquinolones have a dominant market share for bacterial conjunctivitis. However, this drug class is likely to reduce its market share by 7.2% by the end of 2024 due to weak research pipeline. The highest growth rate is witnessed by aminoglycosides, followed by macrolides. However, the loss of patent of blockbuster drugs, such as Moxeza, Besivance, Vigamox, and Zymaxid, has hampered the growth of the market.

Key Players: The major players in the market include Novartis, Valeant Pharmaceuticals International, Teva Pharmaceuticals, and Akron Inc. Perrigo Corporation, Bayer AG, Pfizer, Daiichi Sankyo Inc., Merck & Co., and F. Hoffmann-La Roche are few of the prominent drugs manufacturers in the market.

Competitive Analysis: Many blockbuster drugs are likely to lose their patents in the market, which in turn, has increased the advent of generic drugs with similar efficacy and less cost. Novartis AG is one of the global leaders in the bacterial conjunctivitis market. Vigamox and Moxeza are the key products of the company, which are expected to lose their patents by 2020. This patent expiry is expected to show a negative impact on the company revenue and its market position. Other strategies used by the market players are acquisitions. For instance, in 2015, Shire Plc acquired Foresight Biotherapeutics for a value of \$300 million. This acquisition added experimental eye drop FST-100 into the Shire Plc's portfolio to treat both viral and bacterial conjunctivitis.

Benefits: The report provides complete details about the usage and adoption rate of bacterial conjunctivitis drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
 - 1.1.1 Global Driver for Pharmaceutical Demand:
 - 1.1.2 Pharmaceutical spending region wise
 - 1.1.3 R&D pipeline in pharmaceutical industry
 - 1.1.4 Top pharma drugs by sales in 2017 (\$Million)
- 1.2 Industry Trends
- 1.3 Total Addressable Market

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market (SAM)
- 3.3 Trends of Bacterial Conjunctivitis Drugs Market
- 3.4 Related Markets
 - 3.4.1 Contact lenses
 - 3.4.1.1 Trends of Contact Lens Market
 - 3.4.2 Oncology (Cancer) Drugs
 - 3.4.3 Active pharmaceutical ingredients (APIs)
 - 3.4.4 Over the counter drugs (OTC)

4 MARKET OUTLINE

- 4.1 Market Segmentation
- 4.2 Porter 5(Five) Forces
- 4.3 PEST Analysis

5 MARKET CHARACTERISTICS

5.1 Market Dynamics of Bacterial Conjunctivitis Drugs Market

5.1.1 Drivers

5.1.1.1 Increasing awareness among patient population about pink eye disease

5.1.1.2 Rising prevalence of bacterial conjunctivitis

5.1.2 Opportunities

5.1.2.1 Increasing clinical trials

5.1.3 Restraints

5.1.3.1 Expiry of patents for blockbuster drugs

5.1.3.2 Complex drug development process

5.1.4 DRO – Impact Analysis

5.1.5 Key Stakeholders

6 APPLICATION: MARKET SIZE AND ANALYSIS

6.1 Overview

6.2 Fluoroquinolones

6.3 Aminoglycosides

6.4 Macrolides

6.5 Others

7 REGIONS: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 North America

7.2.1 Overview

7.3 Europe

7.3.1 Overview

7.4 APAC

7.4.1 Overview

7.5 Rest of the World

7.5.1 Overview

8 COMPETITIVE LANDSCAPE

9 VENDOR PROFILES

9.1 Novartis AG

9.1.1 Overview

9.1.2 Business Unit

- 9.1.3 Geographic Presence
- 9.1.4 Business Focus
- 9.1.5 SWOT Analysis
- 9.1.6 Business Strategy
- 9.2 Valeant Pharmaceuticals International Inc.
 - 9.2.1 Overview
 - 9.2.2 Business Unit
 - 9.2.3 Geographic Presence
 - 9.2.4 Business Focus
 - 9.2.5 SWOT Analysis
 - 9.2.6 Business Strategy
- 9.3 Teva Pharmaceutical Industries Ltd.
 - 9.3.1 Overview
 - 9.3.2 Business Unit
 - 9.3.3 Geographic Presence
 - 9.3.4 Business focus
 - 9.3.5 SWOT analysis
 - 9.3.6 Business Strategy
- 9.4 Akron Inc
 - 9.4.1 Overview
 - 9.4.2 Business Focus
 - 9.4.3 SWOT Analysis
 - 9.4.4 Business Strategy

10 COMPANIES TO WATCH FOR

- 10.1 Santen Pharmaceutical Co., Ltd.
 - 10.1.1 Overview
- 10.2 Perrigo Company plc
 - 10.2.1 Overview
- 10.3 Merck & Co.
 - 10.3.1 Overview
- 10.4 Pfizer Inc.,
 - 10.4.1 Overview
 - 10.4.2 Highlights
- 10.5 Daiichi Sankyo, Inc.
 - 10.5.1 Overview
 - 10.5.2 Overview
- 10.6 Bayer AG

- 10.6.1 Overview
- 10.7 F. Hoffmann-La Roche
 - 10.7.1 Overview
- Annexure
- Abbreviations

List Of Tables

LIST OF TABLES

Table 1 PATENT EXPIRATION OF RESPIRATORY DRUGS

Table 2 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY DRUG CLASS, 2017–2024 (\$MILLION)

Table 3 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE BY REGIONS, 2017–2024 (\$MILLION)

Table 4 POPULATION LIVING IN ENDEMIC AREAS OF TRACHOMA BY COUNTRY

Table 5 NOVARTIS AG: OFFERINGS

Table 6 NOVARTIS AG: RECENT DEVELOPMENTS

Table 7 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS

Table 8 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS

Table 9 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERINGS

Table 10 TEVA PHARMACEUTICAL INDUSTRIES LTD: RECENT DEVELOPMENTS

Table 11 AKORN INC: OFFERINGS

Table 12 AKORN INC.: RECENT DEVELOPMENTS

Table 13 SANTEN PHARMACEUTICAL CO., LTD.: OVERVIEW

Table 14 SANTEN PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS

Table 15 PERRIGO COMPANY PLC: OVERVIEW

Table 16 PERRIGO COMPANY PLC: RECENT DEVELOPMENTS

Table 17 MERCK & CO: OVERVIEW

Table 18 MERCK & CO: RECENT DEVELOPMENTS

Table 19 PFIZER: RECENT DEVELOPMENTS

Table 20 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS

Table 21 BAYER AG: OVERVIEW

Table 22 BAYER AG: RECENT DEVELOPMENTS

Table 23 F. HOFFMANN-LA ROCHE: OVERVIEW

Table 24 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS

List Of Charts

LIST OF CHARTS

Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010-2016)

Chart 2 R&D INVESTMENT BY TOP 10 COMPANIES (\$BN)

Chart 3 PHARMACEUTICAL DRUGS BY SALES, 2017

Chart 4 CAUSES OF SIGHT LOSS GLOBALLY

Chart 5 RESEARCH METHODOLOGY OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET

Chart 6 GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 7 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS

Chart 8 SEGMENTATION OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET

Chart 9 PORTER 5 FORCES OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET

Chart 10 PEST ANALYSIS OF BACTERIAL CONJUNCTIVITIS DRUGS MARKET

Chart 11 MARKET DYNAMICS – DRO ANALYSIS

Chart 12 DRO – IMPACT ANALYSIS OF GLOBAL BACTERIAL CONJUNCTIVITIS DRUGS MARKET

Chart 13 KEY STAKEHOLDERS

Chart 14 BACTERIAL CONJUNCTIVITIS DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 VS 2024 (%)

Chart 15 FLUOROQUINOLONES DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 16 AMINOGLYCOSIDES DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 17 MACROLIDES DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 18 OTHER BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 19 BACTERIAL CONJUNCTIVITIS DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)

Chart 20 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (\$MILLION)

Chart 21 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE EUROPE REGION, 2017–2023 (\$MILLION)

Chart 22 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN THE APAC REGION, 2017-2024 (\$MILLION)

Chart 23 BACTERIAL CONJUNCTIVITIS DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 (\$MILLION)

Chart 24 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 25 NOVARTIS AG: BUSINESS UNITS

Chart 26 NOVARTIS AG: GEOGRAPHICAL PRESENCE

Chart 27 NOVARTIS AG: SWOT ANALYSIS

Chart 28 VALEANT PHARMACEUTICALS INTERNATIONAL INC: OVERVIEW
SNAPSHOT

Chart 29 VALEANT PHARMACEUTICALS INTERNATIONAL INC: BUSINESS UNITS

Chart 30 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL
PRESENCE

Chart 31 VALEANT PHARMACEUTICALS INTERNATIONAL INC: SWOT ANALYSIS

Chart 32 TEVA PHARMACEUTICAL INDUSTRIES LTD: OVERVIEW SNAPSHOT

Chart 33 TEVA PHARMACEUTICAL INDUSTRIES LTD: BUSINESS UNITS

Chart 34 TEVA PHARMACEUTICAL INDUSTRIES LTD: GEOGRAPHICAL
PRESENCE

Chart 35 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS

Chart 36 AKRON INC: OVERVIEW SNAPSHOT

Chart 37 AKRON INC.: BUSINESS UNITS

Chart 38 AKRON INC.: SWOT ANALYSIS

I would like to order

Product name: Global Conjunctivitis Drugs Market 2018-2024

Product link: <https://marketpublishers.com/r/G0CDBE1278BEN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0CDBE1278BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970